Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002912 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00002912: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00002912 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002912, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of PSC-833 plus etoposide and mitoxantrone in treating children who have refractory or relapsed acute leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers become resistant to chemotherapy drugs. Combining PSC-833 with chemotherapy may reduce resistance to the drug and allow more cancer cells to be killed.
Interventions
- DRUG etoposide
- DRUG mitoxantrone hydrochloride
- DRUG valspodar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 1997-01 |
| Phase | Phase 1 |
What the finished NCT00002912 record still lists
NCT00002912 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which etoposide is the first listed.
NCT00002912 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002912 about?
NCT00002912 is a clinical study titled "Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia". Phase I trial to study the effectiveness of PSC-833 plus etoposide and mitoxantrone in treating children who have refractory or relapsed acute leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers become resistant to chem...
What is the current status of trial NCT00002912?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 1997-01.
What interventions are being tested in trial NCT00002912?
The interventions under investigation include: etoposide (DRUG), mitoxantrone hydrochloride (DRUG), valspodar (DRUG).
Who is sponsoring clinical trial NCT00002912?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002912's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia